Cite

HARVARD Citation

    Dulloo, S. et al. (n.d.). EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations – real world data. Lung cancer. pp. S40-. [Online]. 
  
Back to record